BR112022021077A2 - Anticorpos humanizados antifator bb de complemento e uso dos mesmos - Google Patents

Anticorpos humanizados antifator bb de complemento e uso dos mesmos

Info

Publication number
BR112022021077A2
BR112022021077A2 BR112022021077A BR112022021077A BR112022021077A2 BR 112022021077 A2 BR112022021077 A2 BR 112022021077A2 BR 112022021077 A BR112022021077 A BR 112022021077A BR 112022021077 A BR112022021077 A BR 112022021077A BR 112022021077 A2 BR112022021077 A2 BR 112022021077A2
Authority
BR
Brazil
Prior art keywords
complement
humanized antibodies
factor
antibodies
factor humanized
Prior art date
Application number
BR112022021077A
Other languages
English (en)
Inventor
Parry Graham
Moore Stephen
Storek Michael
C Leksa Nina
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112022021077A2 publication Critical patent/BR112022021077A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS HUMANIZADOS ANTIFATOR BB DE COMPLEMENTO E USO DOS MESMOS. A presente invenção refere-se a anticorpos humanizados antifator Bb, métodos de produção dos anticorpos e métodos de uso dos anticorpos.
BR112022021077A 2020-04-20 2021-04-19 Anticorpos humanizados antifator bb de complemento e uso dos mesmos BR112022021077A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012590P 2020-04-20 2020-04-20
PCT/US2021/027981 WO2021216458A1 (en) 2020-04-20 2021-04-19 Humanized anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022021077A2 true BR112022021077A2 (pt) 2022-12-13

Family

ID=78221896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021077A BR112022021077A2 (pt) 2020-04-20 2021-04-19 Anticorpos humanizados antifator bb de complemento e uso dos mesmos

Country Status (14)

Country Link
US (1) US11242382B2 (pt)
EP (1) EP4139350A4 (pt)
JP (1) JP2023522102A (pt)
KR (1) KR20230004686A (pt)
CN (1) CN115702165A (pt)
AR (1) AR121881A1 (pt)
AU (1) AU2021261257A1 (pt)
BR (1) BR112022021077A2 (pt)
CA (1) CA3173325A1 (pt)
CO (1) CO2022014878A2 (pt)
IL (1) IL297444A (pt)
MX (1) MX2022013135A (pt)
TW (1) TW202140543A (pt)
WO (1) WO2021216458A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012176A (es) 2016-04-04 2019-02-07 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
KR20150055628A (ko) 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
KR101585532B1 (ko) 2005-12-20 2016-01-14 에스비아이 바이오테크 가부시키가이샤 항-ｉｌｔ7 항체
AU2008293487A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
SG11201401319XA (en) * 2011-10-27 2014-06-27 Nkt Therapeutics Inc Humanized antibodies to inkt
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
AU2013243570B2 (en) 2012-04-03 2017-12-14 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9796776B2 (en) 2014-02-27 2017-10-24 Allergan, Inc. Complement factor Bb antibodies
MX2018000621A (es) * 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
MX2018012176A (es) 2016-04-04 2019-02-07 Bioverativ Usa Inc Anticuerpos anti-factor bb del complemento y usos de estos.
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity

Also Published As

Publication number Publication date
AR121881A1 (es) 2022-07-20
TW202140543A (zh) 2021-11-01
JP2023522102A (ja) 2023-05-26
US11242382B2 (en) 2022-02-08
EP4139350A4 (en) 2024-04-24
IL297444A (en) 2022-12-01
US20220213179A1 (en) 2022-07-07
WO2021216458A1 (en) 2021-10-28
US20210332115A1 (en) 2021-10-28
CN115702165A (zh) 2023-02-14
EP4139350A1 (en) 2023-03-01
CA3173325A1 (en) 2021-10-28
MX2022013135A (es) 2022-11-10
CO2022014878A2 (es) 2023-02-16
KR20230004686A (ko) 2023-01-06
AU2021261257A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
EA202092839A1 (ru) Агенты, связывающиеся с psma, и виды их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
MY186351A (en) Multispecific antibodies
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
AR104250A1 (es) Anticuerpo anti-notch4 humano
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
BR112020015498A8 (pt) Anticorpos anti-pd-1
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
BR112021020357A2 (pt) Anticorpos anti-cd3 de alta afinidade e métodos para sua geração e uso
EA201991876A1 (ru) Антитела против фактора d и их применения
CO2023018064A2 (es) Anticuerpos anti-ccr8 y usos de los mismos
BR112022015902A2 (pt) Anticorpos de cd19 anti-humanos
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
BR112023024837A2 (pt) Anticorpos anti-ccr8